SI2780011T1 - Kombinirana terapija raka jajčnikov - Google Patents

Kombinirana terapija raka jajčnikov Download PDF

Info

Publication number
SI2780011T1
SI2780011T1 SI201231285T SI201231285T SI2780011T1 SI 2780011 T1 SI2780011 T1 SI 2780011T1 SI 201231285 T SI201231285 T SI 201231285T SI 201231285 T SI201231285 T SI 201231285T SI 2780011 T1 SI2780011 T1 SI 2780011T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutically acceptable
ylamine
imidazol
pyridin
fluoro
Prior art date
Application number
SI201231285T
Other languages
English (en)
Inventor
Edward Michael Chan
Susan Elizabeth Pratt
Louis Frank Stancato
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI2780011T1 publication Critical patent/SI2780011T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (9)

  1. KOMBINIRANA TERAPIJA RAKA JAJČNIKOV Patentni zahtevki 1. 5-[2-tert-butil-5-(4-fluoro-fenil)-1 H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamin, ali njegova farmacevtsko sprejemljiva sol za uporabo v kombinirani terapiji z gemcitabinom in sredstvom s platino izbranim med cisplatinom in karboplatinom pri zdravljenju raka jajčnikov.
  2. 2. 5-[2-tert-butil-5-(4-fluoro-fenil)-1 H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamin, ali njegova farmacevtsko sprejemljiva sol, za uporabo po zahtevku 1, pri čemer se administracija 5-[2-tert-butil- 5-(4-fluoro-fenil)-1H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamina, ali njegove farmacevtsko sprejemljive soli, izvede pred gemcitabinom in sredstvom s platino.
  3. 3. 5-[2-tert-butil-5-(4-fluoro-fenil)-1H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamin, ali njegova farmacevtsko sprejemljiva sol za uporabo po zahtevku 1 ali 2, pri čemer se administracija gemcitabina in sredstva s platino izvede do 2 dneva po administraciji 5-[2-tert-butil-5-(4-fluoro-fenil)-1H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamina, ali njegove farmacevtsko sprejemljive soli, in se izvede administracija gemcitabina ponovno do 7 dni pozneje.
  4. 4.
  5. 5-[2-tert-butil-5-(4-fluoro-fenil)-1H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-bJpiridin-2-ilamin ali njegova farmacevtsko sprejemljiva sol za uporabo po zahtevku 1, pri čemer se administracija gemcitabina in sredstva s platino izvede pred administracijo 5-[2-tert-butil-5-(4-fluoro-fenil)-1 H-imidazol-4-il]-3-(2,2-dimetilpropil)-3Himidazo[4,5-b]piridin-2-ilamin, ali njegove farmacevtsko sprejemljive soli. 5. 5-[2-tert-butil-5-(4-fluoro-fenil)-1 H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamin, ali njegova farmacevtsko sprejemljiva sol, za uporabo po zahtevku 1 do 2, pri čemer se administracija gemcitabina in sredstva s platino izvede istočasno.
  6. 6. 5-[2-tert-butil-5-(4-fluoro-fenil)-1H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamin, ali njegova farmacevtsko sprejemljiva sol, za uporabo po zahtevku 1 do 5, pri čemer je sredstvo s platino cisplatin.
  7. 7. 5-[2-tert-butil-5-(4-fluoro-fenil)-1 H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamin, ali njegova farmacevtsko sprejemljiva sol, za uporabo po zahtevku 1 do 5, pri čemer je sredstvo s platino karboplatin.
  8. 8. 5-[2-tert-butil-5-(4-fluoro-fenil)-1H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamin, ali njegova farmacevtsko sprejemljiva sol, za uporabo po zahtevku 1 do 7 med 21-dnevnim ciklom zdravljenja.
  9. 9. 5-[2-tert-butil-5-(4-fluoro-fenil)-1H-imidazol-4-il]-3-(2,2-dimetil-propil)-3H-imidazo[4,5-b]piridin-2-ilamin, ali njegova farmacevtsko sprejemljiva sol, za uporabo po zahtevku 1 do 8, pri čemer je farmacevtsko sprejemljiva sol dimetansulfonatna sol.
SI201231285T 2011-11-11 2012-10-31 Kombinirana terapija raka jajčnikov SI2780011T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558582P 2011-11-11 2011-11-11
PCT/US2012/062634 WO2013070460A1 (en) 2011-11-11 2012-10-31 Combination therapy for ovarian cancer
EP12783804.3A EP2780011B1 (en) 2011-11-11 2012-10-31 Combination therapy for ovarian cancer

Publications (1)

Publication Number Publication Date
SI2780011T1 true SI2780011T1 (sl) 2018-07-31

Family

ID=47146746

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231285T SI2780011T1 (sl) 2011-11-11 2012-10-31 Kombinirana terapija raka jajčnikov

Country Status (30)

Country Link
US (1) US9844529B2 (sl)
EP (1) EP2780011B1 (sl)
JP (1) JP6055481B2 (sl)
KR (1) KR101647569B1 (sl)
CN (1) CN103917233B (sl)
AP (1) AP3881A (sl)
AU (1) AU2012336154B2 (sl)
BR (1) BR112014011197A2 (sl)
CA (1) CA2850559C (sl)
CR (1) CR20140211A (sl)
CY (1) CY1120315T1 (sl)
DK (1) DK2780011T3 (sl)
DO (1) DOP2014000100A (sl)
EA (1) EA026297B1 (sl)
ES (1) ES2671730T3 (sl)
HR (1) HRP20180875T1 (sl)
HU (1) HUE037928T2 (sl)
IL (1) IL232479A0 (sl)
LT (1) LT2780011T (sl)
ME (1) ME03035B (sl)
MX (1) MX2014005698A (sl)
MY (1) MY168927A (sl)
PL (1) PL2780011T3 (sl)
PT (1) PT2780011T (sl)
RS (1) RS57256B1 (sl)
SG (1) SG11201401795XA (sl)
SI (1) SI2780011T1 (sl)
TN (1) TN2014000150A1 (sl)
WO (1) WO2013070460A1 (sl)
ZA (1) ZA201403159B (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
SG10202110259QA (en) 2017-10-05 2021-10-28 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533360A (ja) * 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors

Also Published As

Publication number Publication date
CA2850559C (en) 2016-11-29
AP2014007631A0 (en) 2014-05-31
BR112014011197A2 (pt) 2017-04-25
EP2780011A1 (en) 2014-09-24
SG11201401795XA (en) 2014-09-26
AU2012336154B2 (en) 2017-01-12
CN103917233B (zh) 2018-11-16
KR20140083010A (ko) 2014-07-03
CA2850559A1 (en) 2013-05-16
JP6055481B2 (ja) 2016-12-27
TN2014000150A1 (en) 2015-09-30
US9844529B2 (en) 2017-12-19
HRP20180875T1 (hr) 2018-07-13
AP3881A (en) 2016-10-31
MY168927A (en) 2019-01-08
IL232479A0 (en) 2014-06-30
CR20140211A (es) 2014-06-20
LT2780011T (lt) 2018-05-10
PL2780011T3 (pl) 2018-08-31
DOP2014000100A (es) 2014-06-30
ES2671730T3 (es) 2018-06-08
MX2014005698A (es) 2014-08-21
JP2014533270A (ja) 2014-12-11
CN103917233A (zh) 2014-07-09
PT2780011T (pt) 2018-05-14
WO2013070460A1 (en) 2013-05-16
ZA201403159B (en) 2017-11-29
NZ623622A (en) 2015-07-31
EA026297B1 (ru) 2017-03-31
AU2012336154A1 (en) 2014-04-17
HUE037928T2 (hu) 2018-09-28
CY1120315T1 (el) 2019-07-10
DK2780011T3 (en) 2018-05-28
EA201490766A1 (ru) 2014-08-29
RS57256B1 (sr) 2018-08-31
KR101647569B1 (ko) 2016-08-10
US20140302174A1 (en) 2014-10-09
ME03035B (me) 2018-10-20
EP2780011B1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
IL257847A (en) Derivatives of 8– [6– [3 [- (amino) propoxy] –3 – pyridyl] –1 – isopropyl – imidazo [4, 5 –c] quinoline – 2 – ion as selective kinases of kinase atm for cancer treatment
SI3212174T1 (sl) Postopki zdravljenja okužb z virusom filoviridae
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
BR112013031039B1 (pt) compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
GB201104267D0 (en) Pyrrolopyridineamino derivatives
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
PE20140293A1 (es) Novedosos derivados heterociclicos
RU2018120318A (ru) ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
BR112015018317A2 (pt) composto de fórmula i ou um sal do mesmo, composição farmacêutica, kit, uso de um composto ou sal, método para tratar um distúrbio, método para tratar dor em um animal
JP2015506348A5 (sl)
RU2013149174A (ru) Новое имидазооксазиновое соединение или его соль
MY167797A (en) Macrocyclic purines for the treatment of viral infections
EA201390823A1 (ru) ДВОЙНЫЕ ИНГИБИТОРЫ PI3 КИНАЗЫ/mTOR
EA201590020A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CA2548654A1 (en) Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
SI2041133T1 (sl) Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki
EA201490472A1 (ru) Комбинированная терапия рака hsp90-ингибитором и антиметаболитом
EA201100409A1 (ru) Замещенные производные триазолопиридазина
SI2780011T1 (sl) Kombinirana terapija raka jajčnikov
SG10201809189UA (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
EA201590021A1 (ru) Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
BR112022000341A2 (pt) Derivados de imidazo [4,5-c] piridina como agonistas de receptor semelhante-toll
AR085285A1 (es) Metodos para tratar enfermedades de la retina
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS